FIELD: chemistry.
SUBSTANCE: invention relates to a tosylate of 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulphonamide. Said compound is a crystalline substance and is characterised by x-ray powder diffraction pattern (PXRD), having any three, four, five or six characteristic two-theta (2θ) peaks, selected from a group comprising 9.0, 9.3, 10.0, 10.7, 11.6, 12.5, 12.9, 13.2, 13.8, 14.4, 16.0, 16.6, 17.5, 17.8, 18.1, 21.4 and 23.4° (±0.2° 2θ), when using x-ray radiation CuKalpha1 (wavelength = 1.5406 Å). Invention also relates to use of 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2- fluoro-N-(1,3-thiazol-4-yl)benzenesulphonamide tosylate for making a drug for treating pain, preferably, neuropathic, nociceptive, or inflammatory pain, or for treating a disease associated with high uric acid levels in blood.
EFFECT: 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulphonamide tosylate, having better chemical stability and good solubility in water.
10 cl, 8 dwg, 9 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR APPLYING CYCLOOXYGENASE-2 INHIBITOR FOR TREATMENT AND PROPHYLAXIS OF NEOPLASIA | 1997 |
|
RU2239429C2 |
METHOD FOR TREATING INFLAMMATION OR INFLAMMATION-INDUCED DISEASE IN DOGS | 1996 |
|
RU2253456C2 |
PYRAZOLEPYRIMIDINES | 2005 |
|
RU2412186C2 |
PYRAZOLYL-SUBSTITUTED BENZENESULFONEAMIDE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD OF TREATMENT OF PATIENTS WITH INFLAMMATION OR INFLAMMATION-ASSOCIATED DISEASES | 1994 |
|
RU2139281C1 |
PHARMACEUTICAL COMPOSITION FOR USING IN THERAPY OF MALIGNANT NEOPLASM COMPRISING COMBINATION OF BISPHOSPHONATE, COX-2 INHIBITOR AND TAXOL | 2002 |
|
RU2317819C2 |
NOVEL 1,2-BIS-SULPHONAMIDE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR | 2011 |
|
RU2654213C9 |
SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | 2014 |
|
RU2669367C2 |
2-CYCLOOXYGENASE INHIBITORS AS ANTIANGIOGENIC AGENTS | 1997 |
|
RU2268716C2 |
USE OF EP4 RECEPTOR ANTAGONIST IN TREATMENT OF CARTILAGE DISEASE | 2014 |
|
RU2663620C2 |
PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2606510C2 |
Authors
Dates
2017-01-30—Published
2012-10-19—Filed